Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

This is a safety and efficacy study of botulinum toxin type A in subjects with glabellar frown lines.

Inclusion Criteria:

• Moderate or severe glabellar frown lines
• Female or male, 30 to 65 years of age in good general health
• Women of childbearing potential must agree to use an effective method of birth control during the course of the study
• Willing to refrain from receipt of facial fillers, laser treatments or use of products that affect skin remodeling and causes an active dermal response

Exclusion Criteria:

• Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A such as amyotrophic lateral sclerosis and motor neuropathy, Lambert-Eaton syndrome, and myasthenia gravis
• Muscle weakness or paralysis, particularly in the treatment area
• Active skin disease or infections or irritation at the treatment area
• Facial asymmetry, deep dermal scarring, or inability to substantially lessen the glabellar frown lines by manually spreading them apart
• Treatment with Botulinum Toxin Type A in the face in the last 6 months or in the last 3 months anywhere in the body